Business
MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231
MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n Allowed claims include the treatment of Type 1 and Type 2 DiabetesPatent protects exclusivity for MANF in diabetes inthe US into 2032 SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that the US Patent & Trademark Office has issued US Patent #9,891,231 covering the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) as a treatment for beta cell disorders, including Type-1 and Type-2 diabetes. This patent extends exclusivity for MANF in the treatment of diabetes in the US into 2032. There is strong belief that MANF has significant therapeutic potential across multiple orphan disease areas, as well as in large indications such as diabetes and cardiovascular disease. MANF Therapeutics is preparing to restart IND-enabling development of MANF in 2018 in glaucoma and retinitis pigmentosa, an indication for which MANF has received orphan drug designation.\n Multiple research groups have published data demonstrating the therapeutic potential of MANF in treating diabetes, including data published in the peer-reviewed scientific journal Cell Reports entitled \"MANF Is Indispensable for the Proliferation and Survival of Pancreatic Cells.\" That study demonstrated the therapeutic benefit of MANF in protecting and restoring pancreatic beta cells in vitro and in vivo in animal models of diabetes. The study's authors determined \"lack of MANF in vivo in mouse leads to chronic unfolded protein response (UPR) activation in pancreatic islets. Importantly, MANF protein enhanced cell proliferation in vitro and overexpression of MANF in the pancreas of diabetic mice enhanced cell regeneration. We demonstrate that MANF specifically promotes cell proliferation and survival, thereby constituting a therapeutic candidate for cell protection and regeneration.\" About Amarantus Bioscience Holdings, Inc. Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases ...